Cyclacel Group plc (“Cyclacel”), the UK-based biopharmaceutical company, announced that a poster presented by independent investigators at the American Society for Hematology (ASH) meeting reported that seliciclib (CYC202 or R-roscovitine) killed multiple myeloma cancer cells by causing them to commit suicide. Seliciclib is Cyclacel’s leading Cyclin Dependent Kinase (CDK) inhibitor drug.
